Harrow Health, Inc. (NASDAQ: HROW) announced a new $50 million senior unsecured note offering with an 8.625% coupon, maturing in 2030. The notes will be issued under the same indenture as the $250 million notes issued in September 2025 and will be guaranteed on a senior unsecured basis by the company’s wholly‑owned subsidiaries.
Proceeds will be used for general corporate purposes, including accelerating product launches, funding research and development, and pursuing strategic business development opportunities. The company has recently launched several products—Vevye, IHEEZO, Triesence—and is advancing the NDA for G‑Melt while expanding access through PharmaPack, underscoring the need for additional liquidity to sustain growth momentum.
The new offering extends Harrow’s debt maturity profile and adds liquidity without diluting shareholders. The company’s high leverage—debt‑to‑equity ratio of 4.77 as of Q4 2025—means the 8.625% interest rate will increase interest expense, but the financing is intended to support the company’s expansion plans and maintain flexibility in a competitive ophthalmic market.
Harrow’s Q4 2025 results showed revenue of $89.1 million, up 33.3% year‑over‑year, and net income of $6.6 million. Revenue growth was driven by strong demand in core product segments, offsetting headwinds in legacy lines. The new debt will help the company capitalize on this momentum while funding ongoing pipeline development.
Market reaction to the announcement has been muted, with investors focusing on the company’s recent earnings miss in Q4 2025. While the EPS miss highlighted challenges in translating revenue growth into profitability, analysts have maintained a positive outlook on Harrow’s long‑term prospects, and the company’s strategic use of debt is viewed as a standard financing approach to support growth.
Overall, the $50 million note offering reflects Harrow Health’s strategy to fund product development and market expansion while managing its capital structure. The financing is expected to provide the company with the necessary cash flow to pursue its pipeline and strategic initiatives, albeit with an increased interest burden that will be offset by anticipated revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.